Moderate to Severe Hidradenitis Suppurativa
Conditions
Interventions
Group 1: placebo QW from Day 1/Week 0 to Week 15, then Izokibep 160mg QW from Week 16 to Week 51
Group 2: Izokibep 160 mg QW from Day 1/Week 0 to Week 51
Sponsors
Benner Saskia
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: General 1.Subject has provided signed informed consent including consenting to comply with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol 2.18 to 75 years of age Type of Subject and Disease Characteristics 3.Diagnosis of HS for >= 6 months prior to first dose of study drug 4.Hidradenitis suppurativa lesions present in >= 2 distinct anatomic areas, one of which is Hurley Stage II or Hurley Stage III 5.A total abscess and inflammatory nodule (AN) count of >= 5 at screening and Day 1 prior to enrollment/randomization 6.Subject must have had an inadequate response to oral antibiotics OR exhibited recurrence after discontinuation to, OR demonstrated intolerance to, OR have a contraindication to oral antibiotics for treatment of their HS 7.Must agree to use daily over-the-counter topical antiseptics 8.Subject must be willing to complete a daily skin pain diary Other protocol defined Inclusion criteria may apply
Exclusion criteria
Exclusion criteria: Medical Conditions 1.Draining fistula count of > 20 2.Outpatient surgery <= 8 weeks prior or inpatient surgery <= 12 weeks prior to enrollment/randomization 3.Other active skin disease or condition that could interfere with study assessments 4.History of active inflammatory bowel disease (IBD) OR symptoms within the last year that may be suggestive of IBD 5.Chronic pain not associated with HS 6.Uncontrolled, clinically significant system disease 7.History of demyelinating disease or neurological symptoms suggestive of demyelinating disease 8.Malignancy within 5 years 9.The subject is at risk of self-harm or harm to others 10.Active infection or history of certain infections 11.Tuberculosis or fungal infection seen on available chest x-ray taken within 3 months prior to first dose of study drug or at screening (Exception: documented evidence of completed treatment and clinically resolved) 12.Known history of human immunodeficiency virus (HIV) Other protocol defined Exclusion criteria may apply
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| HiSCR75 at Week 16 | — |
Countries
Canada, France, Germany, Hungary, Japan, Poland, Spain, The United States
Contacts
Public Contactcontact Clinical trial
ICON Clinical Research GK
Outcome results
None listed